France transfers vaccine production technology to Vietnam

NDO - On May 26, under the witness of President Luong Cuong and President of the French Republic Emmanuel Macron, Vietnam Vaccine Company (VNVC) and Sanofi Pharmaceutical Group (France) exchanged a cooperation agreement document on transferring Sanofi's vaccine production technology at the VNVC Vaccine and Biological Products Factory, Vietnam.

The event is an official activity within the framework of the French President's State visit to Vietnam, at the invitation ofPresident Luong Cuong. The visit is of special significance as the two countries have just upgraded their relationship to a Comprehensive Strategic Partnership since October 2024, during the official visit to France by General Secretary To Lam.

The event announcing the signing of a cooperation agreement between VNVC and Sanofi France on vaccine production technology transfer is a clear demonstration of the trust and efforts of both sides to move towards new heights of development in essential fields of the globalization era such as medicine and health care.

The agreement on vaccine production technology transfer between VNVC Vaccine Company and the leading French pharmaceutical group - Sanofi is a concrete demonstration of the realization of strategic cooperation between the two countries, laying the foundation for the development of bilateral relations in the health sector, not only in trade and human resource training, but also in expanding and enhancing cooperation in scientific research, technology transfer, and high-tech vaccine production.

The cooperation is expected to bring great and long-term benefits to the people of the two countries in the fields of medicine and health care, while creating momentum and a solid legal basis for bilateral activities in medicine, pharmaceuticals, and vaccines in the coming time.

This is also an important step for the Vietnamese health sector to expand international cooperation in advanced science and technology, proactively step by step to strengthen national health security, improve the capacity to respond to future epidemic challenges, create a solid foundation for outstanding development in the biomedical field, and bring practical benefits to the people.

According to the cooperation agreement, VNVC and Sanofi will gradually transfer technology to produce some important Sanofi vaccines used in large quantities in Vietnam such as 6-in-1 vaccine for children, flu vaccine, meningococcal meningitis vaccine for both children and adults.

In addition, Sanofi also accompanies VNVC in training human resources and quality management in vaccine research and production.

VNVC and Sanofi will gradually transfer technology to produce some important Sanofi vaccines used in large quantities in Vietnam such as 6-in-1 vaccine for children, flu vaccine, meningococcal meningitis vaccine...

Speaking about the significance of this cooperation, Mr. Ngo Chi Dung, General Director and Chairman of the Board of Directors of VNVC Vaccine Company, said that in the context that the Party and State are creating the most favorable conditions for the development of the private economy, especially in the field of international cooperation in science and technology, the cooperation in technology transfer with Sanofi, France - the world's leading vaccine manufacturer is an important cooperation, helping VNVC in particular, and the Vietnamese vaccine manufacturing industry in general, to quickly improve production capacity to produce high-quality "Made in Vietnam" vaccines on par with the world.

Technology transfer allows Vietnam to quickly access leading modern technologies, optimize research and development activities, promptly serve domestic needs and firmly ensure national health security. Accordingly, Vietnam can proactively produce hundreds of millions of doses of high-quality vaccines each year to serve domestic needs and even export.

Proactive domestic production will help ensure adequate supply of high-quality vaccines and reduce vaccine costs for people. This will be of great significance in the vaccine coverage strategy, protecting the health of all people, thereby reducing the burden of disease, reducing medical examination and treatment costs, and improving the quality of life.

In its strategic vision of contributing to the goal of national vaccine self-sufficiency, VNVC will build a modern VNVC Vaccine and Biological Products Factory, with a scale of up to 26,000m2 in Long An province. With an initial investment of VND 2,000 billion, the VNVC Vaccine Factory is designed to meet the highest standards of Good Manufacturing Practice (GMP) of the World Health Organization (WHO), the European Union (EU), and the US Food and Drug Administration (FDA).

Currently, Sanofi is providing tens of millions of doses of high-quality vaccines to serve the needs of vaccination services in Vietnam such as 6-in-1 Hexaxim, 4-in-1 Tetraxim, 3-in-1 diphtheria-pertussis-tetanus Adacel, Japanese encephalitis Imojev, rabies Verorab, meningococcal meningitis Menactra, hepatitis A Avaxim, quadrivalent influenza Vaxigrip Tetra, typhoid Typhim VI.

It is expected that when these vaccines are produced in Vietnam, there will be an abundant supply and reduced costs, providing the opportunity for full vaccination and protecting the health of many children and adults.

Source: https://nhandan.vn/phap-chuyen-giao-cong-nghe-san-xuat-vaccine-cho-viet-nam-post882425.html